STATE-OF-THE-ART REVIEW

Endothelial- and Immune Cell-Derived Extracellular Vesicles in the Regulation of Cardiovascular Health and Disease

Felix Jansen, MD,a Qian Li, MD,a,b Alexander Pfeifer, MD, PHD,c Nikos Werner, MDa

SUMMARY

Intercellular signaling by extracellular vesicles (EVs) is a route of cell-cell crosstalk that allows cells to deliver biological messages to specific recipient cells. EVs convey these messages through their distinct cargoes consisting of cytokines, proteins, nucleic acids, and lipids, which they transport from the donor cell to the recipient cell. In cardiovascular disease (CVD), endothelial- and immune cell-derived EVs are emerging as key players in different stages of disease development. EVs can contribute to atherosclerosis development and progression by promoting endothelial dysfunction, intravascular calcification, unstable plaque progression, and thrombus formation after rupture. In contrast, an increasing body of evidence highlights the beneficial effects of certain EVs on vascular function and endothelial regeneration. However, the effects of EVs in CVD are extremely complex and depend on the cellular origin, the functional state of the releasing cells, the biological content, and the diverse recipient cells. This paper summarizes recent progress in our understanding of EV signaling in cardiovascular health and disease and its emerging potential as a therapeutic agent. (J Am Coll Cardiol Basic Trans Science 2017;2:790–807) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Cardiovascular disease (CVD) still represents the leading cause of mortality worldwide. The underlying disease, atherosclerosis, is initiated and propagated by continuous damage of the vascular endothelium, leading to endothelial activation and apoptosis, the development of endothelial dysfunction, and subsequent atherosclerotic lesion formation (1). Endothelial cell (EC) injury is a key element in the complex pathophysiology of atherogenesis and triggers the release of EC-derived extracellular vesicles (EVs) such as exosomes and microvesicles (MVs) (2). Accordingly, patients with vascular diseases associated with systemic endothelial damage, such as atherosclerosis, show significantly increased levels of circulating EVs (3,4). However, EVs are not simply inactive debris that reflect cellular activation or injury. EVs can transfer proteins, cytokines, mRNA, or noncoding RNA such as microRNA (miRNA) or long noncoding RNA to target cells and influence their function and phenotype (5,6). Accordingly, the role of EVs has changed from being only a marker of vascular integrity toward being relevant effectors in intercellular vascular signaling (7,8).

From the 1Department of Internal Medicine II, Rheinische Friedrich-Wilhelms University, Bonn, Germany; 2Department of Cardiology, Second Hospital of Jilin University, Nanguan District, Changchun, China; and the 1Institute of Pharmacology and Toxicology, University of Bonn, Bonn, Germany. Drs. Werner, Pfeifer, and Jansen are supported by Deutsche Forschungsgemeinschaft (WE 4139/8-1, JA2352/2-1, DFG GRK1873). Dr. Jansen received support from Medical Faculty of the Rheinische Friedrich-Wilhelms-University Bonn, the Familie Schambach foundation and German Society of Cardiology. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Jansen and Li contributed equally to this study. All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.

Manuscript received July 7, 2017; revised manuscript received August 14, 2017, accepted August 14, 2017.
contribute to disease development and progression by promoting initial lesion formation, intravascular calcifications, plaque progression, and thrombus formation after rupture. In contrast, numerous studies have demonstrated that certain subtypes of EVs can mediate vascular protection and endothelial regeneration (9). In line with these findings, EVs released by progenitor or mesenchymal stem cells have been shown to improve cardiac function after myocardial infarction in experimental studies, highlighting the therapeutic potential of EVs in cardiovascular pathologies (10). This review summarizes current knowledge of EVs as regulators of cardiovascular health and disease and potential opportunities for therapeutic use.

**BIOGENESIS OF EXTRACELLULAR VESICLES AND THEIR INTERACTIONS WITH TARGET CELLS**

EVs are membrane vesicles secreted from cells that contain intracellular contents (11). Cells can release a broad range of vesicles with diverse features. This review focuses on 2 major types: MVs and exosomes. MVs are large (>150 nm) vesicles that are released by budding from the plasma membrane, whereas exosomes are smaller (30 to 100 nm) and originate from the endosome (12). However, there is no strict cutoff value that distinguishes MVs from exosomes by vesicle size, which can differ in diverse studies (12).

Exosomes represent a homogenous population of vesicles that are formed by inward budding of the multivesicular body (MVB) membrane. Exosome biogenesis is mediated mainly by the endosomal sorting complex required for transport (ESCRT) protein (13) or lipid ceramide and neutral sphingomyelinase, the enzyme that converts sphingomyelin to ceramide (14). Cargo sorting into exosomes involves ESCRT and associated proteins such as tumor susceptibility gene 101 protein (TSG101) and ALG-2-interacting protein X (ALIX) and small GTPases such as Rab7a and Rab27b (15-17). Exosomes are liberated into the extracellular space following fusion of MVBs with the cell membrane, regulated by Rab27A, Rab11, and Rab31 (18,19). MVs represent a relatively heterogeneous population of vesicles formed by outward budding of the cell membrane. This process is regulated by membrane lipid microdomains and regulatory proteins such as ADP-ribosylation factor 6 (ARF6) (20). EVs can be regarded as intercellular messengers for various biological processes. Several routes of interaction between EVs and recipient cells have been described. First, EVs can directly activate target cell surface receptors by bioactive ligands and proteins (21-23). Second, EVs are able to transfer their biological content by membrane fusion with the recipient cell. The fusion process is regulated by the lipid composition of EV membrane, and several reports indicate that the presence of phosphatidylinerine contributes to membrane fusion (24). Third, incorporation of EVs into target cells is mediated by endocytosis, pinocytosis, or phagocytosis (25). Through these interaction routes, EVs transfer their biological contents containing nucleic acids such as mRNA (26), noncoding RNAs (miRNAs [27], long noncoding RNAs [6]), proteins (28), cytokines (29), or bioactive lipids (30) (Figure 1).

**EXTRACELLULAR VESICLES AS EFFECTORS OF CARDIOVASCULAR DISEASES**

In cardiovascular biology, EVs have various physiological functions, including activation of platelets and ECs, as well as regulation of inflammation and coagulation (31-34). Therefore, EVs are emerging as key players in different stages of CVD development (31,32,35). The effects of EVs in CVD are extremely complex and depend on the cellular origin, the functional state of the releasing cells, the intravesicular content, and the recipient cells (36,37). The following sections summarize the current knowledge about EVs as effectors of CV disease progression or vascular repair.

**DETRIMENTAL EFFECTS OF EXTRACELLULAR VESICLES ON VASCULAR FUNCTION.** Endothelial dysfunction occurs as a response to cardiovascular risk factors and represents the initial step in atherosclerosis development, the underlying pathology of CVD (38,39).

**Endothelial dysfunction.** Endothelial MVs have been shown to impair vasorelaxation by inhibiting nitric oxide (NO) production in target ECs. This phenomenon is mediated through a decrease in endothelial NO synthase phosphorylation and activity (40), local oxidative stress (41), or an increased NADPH oxidase activity with MVs (33) and results in impaired vascular relaxation capacities. MVs in the aforementioned studies are obtained from ECs under physiological (40,41) or pathological (33) conditions, but they all have detrimental effects on vasorelaxation. Regarding the relation between molecular contents and function of EVs, further investigation should be conducted to clarify and compare the cargoes of EVs derived under different conditions (e.g., by RNA sequencing or proteomic analysis).
In line with the latter findings, MVs isolated from patients with vascular (acute coronary syndrome [42]) or predisposing disease (chronic renal failure or metabolic syndrome [43,44]) were shown to induce endothelial dysfunction ex vivo in rat aortic rings. In contrast, MVs from healthy subjects did not affect endothelial function(42–44), indicating that the pathophysiological state of the releasing cell determines not only the number of released MVs but also their content and biological function. Which cell-specific MVs mainly influence endothelial function and whether isolated MVs from different cell types may have diverse biological functions need to be addressed in future studies.

Of interest, storage of human blood under standard blood-banking conditions results in accumulation of MV-encapsulated hemoglobin. These erythrocyte-derived MVs react with and degrade NO, inducing endothelial dysfunction(45). Finally, platelet-derived exosomes derived under septic conditions have been shown to mediate septic endothelial dysfunction by inducing endothelial apoptosis involving superoxide, NO, and peroxynitrite production (46). Studying EVs derived from patients...
represents an important translational approach to exploring the relationship between EVs and certain diseases. However, comorbidities as well as patients’ age and sex should be taken into consideration as possible confounders. Therefore, inclusion and exclusion criteria should be thoughtfully determined, and control groups must be carefully selected.

**Endothelial activation, monocyte adhesion**/infiltration, **and inflammation**. Inflammation plays a pivotal role in CVD (38,47). EVs from various cellular sources contribute to vascular inflammatory processes including endothelial activation, monocyte adhesion, and transmigration (48-51).

In vitro studies have demonstrated that MVs can induce release of the proinflammatory cytokines interleukin (IL)-6 and IL-8 from ECs and leukocytes (52,53); and promote expression of adhesion proteins ICAM-1, VCAM-1, and E-selectin, facilitating increased adhesion of monocytes (54,55) and subsequent transmigration, leading to vascular inflammation and plaque development. Mechanically, increased adhesion of monocytes to ECs can be mediated by the MV-mediated transfer of proinflammatory molecules such as oxidized phospholipids (56), caspase-3 (57), or RANTES (regulated on activation, normal T cell expressed and secreted) protein, which is transferred from platelet MVs to endothelial target cells (58). Platelet MVs from apoptotic platelets also facilitate differentiation between resident macrophages and professional phagocytes (59). Vascular inflammatory processes involve different cells (e.g., ECs, monocytes, and platelets [48-51]). The aforementioned in vitro studies demonstrated that EVs from diverse parent cells can act on various types of target cells. In summary, vascular inflammation seems to be regulated by complex intercellular communication routes involving a network of cells and EVs. To gain more insight into these multifaceted mechanisms, co-incubation of different EVs with diverse cell types may be helpful to study this “intercellular communication network.” However, there is a lack of adequate in vitro models, which should be addressed in further studies.

Pathological conditions modify EV content and biological functions (60). MVs isolated from atherosclerotic plaques transfer ICAM-1 to ECs and recruit inflammatory cells, suggesting that human plaque MVs promote atherogenesis (24).

Moreover, oxidatively modified, but not native, EC-derived EVs contain proinflammatory oxidized phospholipids that elicit specific responses in ECs, leading to the adhesion of monocytes (56). In line with these findings, EC-derived EVs generated from glucose-treated cells, but not from healthy ECs, facilitated up-regulation of ICAM-1 and VCAM-1 in endothelial target cells by activating p38 in a reactive oxygen species-dependent manner (33). In light of these proinflammatory effects and the increased levels of endothelial MVs in diabetic patients, one may speculate that MVs released under pathological high-glucose conditions might represent a paracrine mediator transporting proinflammatory messages to target cells and thereby foster vascular inflammation (61,62). However, while studying the functional effects of EVs derived under pathological conditions, one must consider that the quantity and/or content of EVs may vary with different modes and durations of stimulation. Therefore, clearly defined pathological conditions (including standardized concentrations and duration of cell stimulations) as well as a careful selection of an adequate control group are mandatory to elaborate EV functions depending on the parent cell conditions.

Compared with the role of MVs, the role of exosomes in vascular inflammatory processes has been less explored (63,64). However, monocyte-derived exosomes seem to induce vascular inflammation and cell death by transferring inflammatory molecules into ECs resulting in a significant up-regulation of ICAM-1, CCL2, and IL-6 levels (65) and provocation of endothelial apoptosis by tissue factor release (66).

**Atherosclerotic plaque development, progression, and rupture.** Atherosclerotic plaque rupture with subsequent coronary thrombosis represents the ultimate step in atherosclerotic lesion progression, leading to acute myocardial ischemia. Atherosclerotic plaques can release large amounts of EVs, contributing to plaque progression and instability through various mechanisms. Plaque EVs originate mainly from leukocytes, reflecting the local inflammatory environment (67). Plaque EVs express surface antigens consistent with their leukocyte origin, including major histocompatibility complex classes I and II, and dose-dependently induce T-cell proliferation (68). Antigen-specific activation of CD4 T cells was also induced by dendritic exosomes, implicating their potential involvement in vascular inflammation and plaque development (69). Furthermore, plaque MVs carry catalytically active tumor necrosis factor (TNF)-
\-converting enzyme (TACE/ADAM17) and significantly enhance the processing of its substrates TNF-\ and TNF receptor, thereby promoting an inflammatory response (70). Importantly, plaque EVs from patients or in vivo models are not single-component molecules, although mainly of leukocyte origin (67), and their constitutions may also depend on the stage of plaque progression (stable or unstable?).
Therefore, standard procedures to derive and analyze plaque EVs should be established.

Local inflammation is enhanced by monocytic MVs fostering leucocyte adhesion to postcapillary venules and T-cell infiltration in atherosclerotic plaques in vivo (71,72). Exosomes from T cells also can contribute to atherosclerotic plaque development by inducing cholesterol accumulation in human monocytes by the phosphatidylserine-receptor (73).

Vascular smooth muscle cell (VSMC) proliferation plays an important role in atherosclerotic plaque development (39,74). The effect of MVs on VSMC proliferation depends on the cellular origin. In vitro-generated platelet-derived MVs promoted VSMC proliferation in a platelet-derived growth factor (PDGF)-independent mechanism with minor effects on migratory capacity (75,76). In turn, monocyte-derived MVs were shown to deliver a lethal message by encapsulated caspase-1-inducing VSMC cell death (77). More recently, calcification-competent EVs derived from smooth muscle cells, valvular interstitial cells, and macrophages have been described as mediators of vascular calcification that modulate heart valve disease and atherogenesis (78–80). Although EVs show protective effects against heart valve calcification, the potential underlying mechanisms are unknown and should be addressed in future studies.

Angiogenesis is a fundamental process in CVD, contributing to plaque instability by promoting neovascularization. Unstable plaques are characterized by an increased number of vasa vasorum mediating intraplaque hemorrhage (81). MVs isolated from human atherosclerotic plaques were shown to stimulate EC proliferation in vitro after CD40 ligation and to enhance in vivo angiogenesis. Interestingly, the proliferative effect of MVs isolated from atherosclerotic plaques was more pronounced using MVs from symptomatic patients than from patients without symptoms. Therefore, MVs could represent a major determinant of plaque vulnerability (82). Unstable human plaques contain large numbers of procoagulant MVs, originating mostly from leucocytes, erythrocytes, and VSMCs localized within the necrotic core (83). Once plaque rupture occurs, these MVs can initiate the coagulation cascade through different mechanisms (67,84): first, by the expression of tissue factor (mainly on monocytic MVs), one major initiator of blood coagulation (34,85,86); and second, by exposure to phosphatidylserine on their outward membrane layer (87). Procoagulatory effects of MVs have been demonstrated in vitro and in vivo, where they facilitated thrombus formation (88,89). The deleterious effects of EVs inducing vascular inflammation, plaque progression, and rupture are illustrated in Figure 1.

In summary, a broad body of evidence indicates the active involvement of EVs in plaque development, progression, and thrombus formation after rupture. However, there is an urgent need for additional mechanistic studies to explore how their atheroprone effects can be targeted to decelerate atherosclerotic lesion formation and rupture.

FAVORABLE EFFECTS OF EXTRACELLULAR VESICLES ON VASCULAR FUNCTION. Despite the various deleterious effects of EVs in the pathogenesis of CVD, an increasing body of evidence highlights the beneficial effects of certain EVs on vascular function. The following sections summarize the impact of EV on endothelial repair, their inhibitory effect on vascular inflammation, and their role in plaque stabilization.

Endothelial protection and vascular repair. Given that EC injury is not only a key element in the complex pathophysiology of atherogenesis but also in in-stent restenosis occurring after treatment of coronary stenosis (90,91), a mechanistic understanding of EC repair is pivotal to develop therapeutic strategies to preserve endothelial integrity and vascular health. Several studies have shown that EVs particularly of endothelial origin can act as intercellular messenger to promote endothelial regeneration and vascular protection in vitro and in vivo.

A potential contribution of endothelial EVs in EC survival was shown by Abid Hussein et al. (92), who demonstrated that endothelial MV release is cell protective by exporting caspase-3 into EVs and thereby diminishing intracellular levels of proapoptotic caspase-3. Statins seem to facilitate endothelial health by promoting endothelial MV release in vitro (93). Nevertheless, the role of statins in endothelial MV release is still a matter of debate (94,95). Our group has demonstrated that annexin I/phosphatidylserine receptor-dependent endothelial MV incorporation by ECs protects endothelial and endothelial-regenerating cells against apoptosis (96). Inhibition of p38 activity by annexin I-containing endothelial MV is possibly involved in endothelial MV-mediated protection. However, whether annexin I also mediates endothelial EV uptake in vivo will be explored in additional animal models. Another study showed that platelet-derived EVs induced changes in the early outgrowth cell, secretome, toward a more proangiogenic profile and amplified the early outgrowth cell-mediated induction of endothelial regeneration in vitro and in vivo (97). These studies indicate that EVs may influence the endothelial regeneration by the following 2 mechanisms: they
could directly interact with ECs and promote vascular regeneration, or they may activate endothelial progenitor cells, facilitating endothelial repair (96,98). In line with these findings, endothelial MVs carrying endothelial protein C receptor and activated protein C (APC) could also promote cell survival by induction of cytoprotective effects (99).

Among the biological contents transferred by EVs into target cells, miRNAs seem to play a crucial role by affecting mRNA and protein expression in recipient cells (100–102). Studies by our group have shown that endothelial MVs promote vascular endothelial repair by delivering functional miRNA-126 into recipient endothelial and vascular smooth muscle cells (103,104). Of note, endothelial MV-mediated miRNA-126-induced endothelial repair was altered under pathological hyperglycemic conditions (103). These findings emphasize the fact that endothelial MVs can stimulate endothelial repair by functionally influencing migration and proliferation capacities in target cells, in addition to the already described regenerative potential of endothelial MV in interaction with progenitor cells. However, although miRNA-126 plays an important role in vascular health, miRNA-126-mediated downstream signaling and processing are not clearly identified and must be addressed in future research. Of note, EVs could activate EC by mRNA transfer from endothelial progenitor cells stimulating angiogenesis (105). In line with these findings, MVs from ischemic muscle promoted progenitor cell differentiation and subsequent postnatal vasculogenesis (106). Besides MVs, exosomes also play an important role in cardiovascular regeneration. Exosomes derived from mesenchymal stem cells reduced myocardial ischemia/reperfusion injury (107). Furthermore, exosomes from cardiac progenitor cells increased the migratory capacity of ECs in vitro and may contribute to vascular...
regeneration in vivo (108). Moreover, CD34+ exosomes promoted angiogenesis and preserved cardiac function in ischemic myocardium by delivery of sonic hedgehog (109).

In summary, EVs derived from endothelium, platelets, or endothelium-regenerating cells play a fundamental role by facilitating regenerative processes after vascular or myocardial injury (10,110,111). Anti-inflammatory effects of extracellular vesicles. Several studies have reported anti-inflammatory effects of EVs. Of interest, neutrophils secrete MVs, which in turn promote anti-inflammatory release of transforming growth factor (TGF)-β1 from macrophages. These findings suggest MVs are potent anti-inflammatory effectors, which at an early stage of inflammation could contribute to its resolution (112). This effect seems to be mediated by annexin I expression on the surface of these EVs (113). EVs are also taken up by monocytes and B cells through diverse mechanisms and affect target cells toward an anti-inflammatory phenotype (114). Mesenchymal stem cells contribute to inflammatory

| TABLE 1 | Detrimental and Favorable Effects of Extracellular Vesicles on Vascular Function |
|----------|-----------------------------------------------------------------------------|
| Effect   | EV Type                         | Isolation Method | Donor Cell/Origin | In Vitro Experiment | In Vivo Experiment | Effects                  | Mechanisms                                      | Ref. # |
| Detrimental effects                                                                                |
| Injured endothelial MVs                      | Centrifugation 20,000 g         | Glucose-treated HCAECs | HCAECs ApoE−/− mice | Induce EC inflammation | Up-regulate ICAM-1 and VCAM-1 in EC by activating p38 | (33) |
| Endothelial MVs                             | Ultracentrifugation 100,000 g   | RMVECs | Aortic rings from rats | Impair vasorelaxation | Local oxidative stress | (41) |
| Circulating MVs                             | Centrifugation 13,000 g         | Patients with MI | Aortic rings from rats | Vasomotor dysfunction | Impair endothelial NO transduction pathway | (42) |
| Erythrocyte MVs                             | Differential centrifugation     | Human packed red blood cells under standard blood banking conditions | – | Rat vasoactivity models | Reduce vasoconstrictor effects | Degrade vasodilator NO | (45) |
| Platelet exosomes                          | Ultracentrifugation 100,000 g   | Platelets from septic patients | ECs | – | Induce ECs apoptosis | Superoxide; NO and peroxynitrite production | (46) |
| PMN MVs                                    | Ultracentrifugation 100,000 g   | PMNs from healthy volunteers | HUVECs | – | Induce ECs activation | Stimulate EC cytokine release Induction of tissue factor | (53) |
| Oxidized MVs                               | Ultracentrifugation 100,000 g   | Oxidatively modified HUVECs | Monocytes | – | Stimulate monocytes adhesion to ECs | Contain oxidized phospholipids | (56) |
| Plaque MVs                                 | Centrifugation 20,500 g         | Human atherosclerotic plaques | HUVECs | – | Promote inflammatory response | Carry catalytically active TNF-α converting enzyme (TACE/ADAM17) Enhance the processing of TNF-α and TNF receptor | (70) |
| Monocyte MVs                               | Ultracentrifugation 100,000 g   | Human peripheral blood monocytes | VSMCs | – | Induce VSMCs cell death | Deliver cell death message via encapsulated caspase-1 | (77) |
| CD40 ligand plus plaque MPs                 | Centrifugation 20,500 g         | Human atherosclerotic plaques | HUVECs Wild-type and B6C3 Nude mice | Stimulate endothelial proliferation and angiogenesis | CD40L signaling | (82) |

Continued on the next page
repression by releasing exosomes that induce secretion of anti-inflammatory cytokines such as IL-10 and TGF-β (115). Administration of mesenchymal stem cell-derived exosomes in a myocardial ischemia/reperfusion injury model resulted in a significant reduction of local and systemic inflammation after 24 h (116). In a renal ischemia/reperfusion model in rats, intravenously administered mesenchymal stem cell-derived exosomes resulted in a significant reduction of renal tubular injury and inflammation (117).
cell-derived MVs limited inflammation as well as renal fibrosis (117). Finally, endothelial MVs promoted anti-inflammatory effects in vitro and in vivo by reducing endothelial ICAM-1 expression by the transfer of functional miRNA-222 into recipient cells (118). In line with these data, ECs suppressed monocyte activation through secretion of exosomes containing anti-inflammatory miRNAs (119). Importantly, despite a large amount of in vitro cellular studies, more in vivo models exploring local and systemic inflammation should be applied to validate and confirm the anti-inflammatory effects of EVs.

**Plaque stabilization and antithrombotic effects.** miRNA-containing EVs have been shown to promote vascular protection and plaque stabilization through various mechanisms. Injection of miRNA-126-3p-enriched apoptotic bodies of endothelial origin promoted atheroprotective effects by limiting plaque size, increasing plaque stability, and enhancing progenitor cell recruitment. miRNA-126-dependent inhibition of regulator of G protein signaling (RGS16) and subsequent enhancement of CXCR4 and CXCL12 was elaborated as the underlying mechanism (27). Exosomes from KLF-2-transduced or shear-stress-stimulated ECs are enriched in miRNAs 143 and 145. By transferring functional miRNAs, EVs were shown to control target gene expression in vascular smooth muscle target cells and reduce atherosclerotic lesion formation in the aorta of apolipoprotein E knockout mice. These findings suggest that atheroprotective stimuli induce communication between ECs and vascular smooth muscle cells through miRNA-transferring EVs (120). Similarly, circulating miRNA-223-containing exosomes could penetrate the vascular wall and inhibit vascular smooth muscle cell proliferation and migration, resulting in decreased plaque size (121). Whereas MVs are involved in enhancing blood clotting processes, exosomes seem to suppress platelet aggregation and occlusive thrombosis by inhibiting platelet CD36, inducing antithrombotic effects. However, further research is needed to validate these findings in adequate in vivo models and to understand the opposing roles of exosomes and MVs in this context. Finally, platelet-derived exosomes reduced CD36-dependent oxidized low-density lipoprotein binding and macrophage cholesterol loading, potentially contributing to atheroprotection (122). Figure 2 illustrates the known beneficial effects of EVs in the regulation of vascular integrity. Table 1 summarizes the most important characteristics of studies exploring the effect of EVs on vascular health and disease.

In conclusion, beneficial and detrimental effects of EVs have been described in the regulation of vascular health and disease. However, there are no constant rules showing a clear relationship between origin and function of EVs. EVs derived under pathological conditions can induce cardiovascular harm (e.g., plaque EVs promote inflammatory response (70)) but also demonstrate atheroprotective functions (e.g., MVs from ischemic muscle induce progenitor cell differentiation (106)). Even the same original EVs can show both detrimental and favorable effects (e.g., endothelial EVs impairing vasorelaxation on one hand (41) and reducing neointima formation on the other hand (104)). In order to clarify the multifaceted character of EVs and make data more comparable, additional efforts should be put into standardized EV generation techniques. Once they are established, in-depth exploration of EV-incorporated and transferred biological molecules and their intracellular processing is necessary to gain more clarity in the understanding of EV function.

**THERAPEUTIC POTENTIAL OF EXTRACELLULAR VESICLES IN CARDIOVASCULAR DISEASES**

**EXTRACELLULAR VESICLES AS NOVEL THERAPEUTIC TOOL?** EVs have emerged as vectors for transferring biological information by proteins or genetic material, thereby maintaining vascular homeostasis, favoring endothelial repair, or even limiting atherosclerosis.

Due to these beneficial effects, there has been a rising interest in the potential use of EVs as therapeutic vectors in the field of cardiovascular medicine and regenerative therapy. Multiple studies have shown that the transfer of functional miRNAs into target tissue by EVs promotes vascular regeneration and atheroprotection (27,103,119,120,123), highlighting the therapeutic potential of miRNA-transferring EVs. In addition to miRNA-containing EVs, many reports describing nanoparticles as a new approach to transport miRNAs or anti-miRNAs to recipient cells have been published recently (124–126) (Figure 4).

Chen et al. (124) developed miRNA-34a-containing liposome-polycationhyaluronic acid (LPH) nanoparticle for systemic delivery of miRNA-34a into lung metastasis of murine melanoma, resulting in significant down-regulation of surviving expression in the metastatic tumors, as well as reduced tumor. Furthermore, biodegradable polymer nanoparticles coated with cell-penetrating peptides for an effective delivery of chemically modified oligonucleotide...
analogue has been described. This nanoparticle system was used to block the activity of the onco-
genic miRNA-155, as well as to attenuate the expression of the proto-oncogene Mcl-1, leading to reduced cell viability and pro-apoptotic effects in the recipient cells (127). Another approach targeting miRNA-155 described decelerated tumor growth after application of polymer nanoparticles containing antisense peptide nucleic acids with subsequent miRNA-155 inhibition (125). An integrin avb3-targeted nanoparticle was used by Anand et al. (128) to deliver anti-
miRNA-132 to the tumor endothelium of human breast carcinoma in mice, causing restored p120Ras-
GAP expression in the tumor endothelium, thereby suppressing angiogenesis and decreasing tumor burden. Although these studies focused on miRNA or anti-miRNA delivery using nanoparticles mainly as a therapeutic tool to combat cancer, it is reasonable that nanoparticles can also be used to deliver miRNAs to recipient vascular cells for tackling inflammation and development of atherosclerosis (129). In this context, magnetic nanoparticle-assisted (circumfer-
tential) gene transfer into the vascular endothelium has recently been described as a promising novel strategy to transfer biological messages into the diseased vasculature (130–132).

**TRANSLATION INTO CLINICAL USE.** EVs have multiple advantages over currently available drug delivery vehicles, such as their ability to overcome natural barriers, their intrinsic cell-targeting properties, protection of their biological cargo from degrading enzymes, and stability in the circulation (133). EV subpopulations could be used as a cargo...
system for efficient and selective drug delivery to a distinct cell type within diseased tissues. This approach offers the additional advantages of low immunogenicity because patient-derived tissue could be used as the source of individualized and biocompatible drug delivery vehicles (134,135) (Figure 3).

Interestingly, tumor cells incubated with chemotherapeutic drugs are able to package these drugs into EVs, which can be collected and used to effectively kill tumor cells in murine tumor models without typical side effects (136). Moreover, tumor cell-derived EVs were used as a unique carrier system to deliver oncolytic adenoviruses to human tumors, leading to highly efficient cytolysis of tumor cells. These findings highlight a novel adenovirus delivery system with promising clinical applications (137).

An important issue regarding EV therapeutics is the biodistribution of EVs. Intravenously injected EVs are of particular interest in the treatment of cardiovascular alterations, as the entire vascular network would be exposed to EVs. However, to selectively deliver EVs to target cells or tissue, cell-specific ligands must be stably expressed on the surface of EVs. Using an innovative approach of donor cell engineering with target cell-specific ligand expression resulted in targeted delivery of short interfering RNA (siRNA) and miRNA-loaded EVs to target neurons (138) and breast cancer cells (139).

Despite promising perspectives for the treatment of cardiovascular pathologies, EV-based therapies still need more investigation to translate experimental data into clinical application. One challenge would be to control the fragile equilibrium between the harmful and beneficial effects reported for EVs in the context of CVD. Furthermore, the off-side effects and clearing mechanisms of EVs need to be better explored before they can be seriously considered as a novel therapeutic tool for combatting CVD (140).

STUDY LIMITATIONS AND METHODOLOGICAL OBSTACLES IN EV RESEARCH. Despite the emerging role of EVs as regulators of health and disease, there...
are still general limitations in EV research. Within this paragraph, we highlight relevant obstacles, which need to be addressed to better understand EV functions and move the EV field forward.

**Methodological obstacles in isolating EVs.** Isolation and purification of EVs vary between different research groups and also depend on the donor cells from which they are derived. Therefore, EV classification, isolation, and purification needs to be standardized to ensure that EV analysis is reproducible and internationally comparable among different research groups (141). Furthermore, within EV populations, many distinct subtypes of vesicles exist. However, the currently used methods (differential ultracentrifugation, polymer-based precipitation, density gradients, microfiltration, size-exclusion-based approaches, or polyethylene glycol (PEG)-mediated isolation techniques) all have different pros and cons in attempting to isolate pure EVs with a distinct size and surface markers (142). The most commonly used isolation methods are differential centrifugation, followed by ultracentrifugation. Two major problems with these techniques are the relatively long procedure times and low throughput, limiting their application in the clinical setting (143). Moreover, the yield depends on the viscosity of biological fluids, so the samples with a relatively high viscosity such as plasma would significantly reduce production (144). Density gradient isolation can promote both the yield and purity of EVs compared with ultracentrifugation; however, the procedure is time-consuming and hard to standardize (145). Ultrafiltration is time-efficient and can concentrate EVs up to 240-fold, but the low purity of EVs is an obstacle (146).

Commercial EV precipitation kits are based mainly on PEG. Although the PEG-mediated technique provides a high-yield, rapid, and inexpensive EV isolation method from both culture media and body fluids, some other contaminants are also copurified, leading to the low purity of EVs (142,147). In the clinical setting, size-exclusion chromatography and affinity capture are the 2 methods most often applied to isolate EVs. Size-exclusion chromatography can remove most soluble components and is a relatively quick procedure with good reproducibility (148), but it also faces the possible problem of protein or RNA contamination (143). Compared with other methods, affinity capture can produce subpopulations of EVs with relatively high purity, but the cost of preparation (antibody based) may limit its applicability and may damage surface proteins and functionality of EVs (143). Therefore, the development of new, more selective isolation techniques is urgently needed to increase the purity of each vesicle subpopulation (149). The pros and cons of each available method are summarized in Table 2.

**Size measurement techniques for EV characterization.** Size is an important defining property of EVs, and measurement of diameter to determine a size distribution is a critical step for EV studies. Size distribution measurement technologies include electron microscopy (EM), flow cytometry (FC), nanoparticle tracking analysis, resistive pulse sensing, and atomic force microscopy (AFM). Although these techniques are commonly used in practice (142), some issues are still unsolved. First, the ideal size measurement should detect EVs with a diameter of 50 nm and larger (150), but most methods, except for EM, cannot detect the smallest EVs (151). Second, the results of size distribution, even for the same EV subpopulation,
Many types of cells release EVs, such as exosomes and microvesicles, by different mechanisms. EVs have both favorable and detrimental effects on vascular integrity. The use of genetically modified EVs might represent a novel therapeutic tool in the field of cardiovascular medicine and regenerative therapy. EV = extracellular vesicles; miRNA = microRNA.
may show different results depending on the method used (152). Furthermore, there are no standard protocols (e.g., optimal EM-EV measurement protocols) (142). Importantly, some methods, such as nanoparticle-tracking analysis or resistive pulse sensing, cannot distinguish membrane vesicles from nonmembranous particles of similar size, so the results should be compared by using EM, AFM, or other microscopy technique (153).

**Regulation of EV packaging.** Although some key players in sorting of cargoes into EVs are revealed (e.g., sumoylated hnRNPA2B1 is reported to control the location of miRNAs into exosomes through binding to specific motifs [154]), the underlying mechanisms mediating the packaging and loading of selected molecules into EVs remain largely unknown. Therefore, additional studies exploring EV biogenesis and mechanisms regulating EV packaging are important to understand cardiovascular injury and repair induced by EVs (155).

**Methodological issues on EV uptake experiments in vitro.** EV uptake experiments are usually performed by direct visualization. Therefore, fluorescent lipid membrane dyes, such as PKH26 (156), PKH68 (157), or rhodamine B (158), are used to stain EV membranes. One potential issue with membrane-binding dyes is that fluorescent molecules could potentially affect the uptake and biological behavior of EVs. However, EV incorporation has been observed with many different lipid-binding dyes, suggesting that such molecules do not affect internalization of vesicles; nevertheless, additional studies are needed to verify whether the biological behavior of EVs is affected by dyes. Another potential limitation of the use of lipophilic dyes is leaching of the fluorescent molecules from EVs into cellular membranes, potentially leading to a pattern of internalization that is due to normal membrane recycling rather than EV uptake. However, direct measurement of the fluorescence transfer rate between EVs and recipient cells support the idea that the increased fluorescence in cells is due to specific uptake of EVs rather than nonspecific dye leaching (159). Another issue which must be considered is the fact that most EV uptake studies have relied on fluorescence microscopy, which has limited resolution because the wavelength of visible light is approximately 390 to 700 nm; therefore, single EVs or aggregated vesicles, which are <390 nm in diameter, cannot be distinguished. This should not affect the assessment of EV uptake in general but may affect the visualization and dynamic localization analysis of individual EVs. Nevertheless, the increasing use of confocal microscopy has confirmed that EVs smaller than 390 nm such as exosomes can be incorporated into recipient cells (160).

**Lack of EV secretion and uptake models in vivo.** The secretion of EVs by parent cells and uptake by recipient cells are precisely regulated. However, few data are available studying concrete mechanisms regulating MV release and clearance. Moreover, physiological models are not well established (e.g., considering time-dependent release kinetics of EVs from parent cells). Finally, the absence of adequate in vivo models to explore the generation and uptake of cell-specific EVs limits the experimental opportunities to study EV functions in vivo.

**Unclear processing of EVs and their content after cellular uptake.** EVs interact with recipient cells by transferring their biological contents through membrane fusion in a ligand-receptor-mediated way or by endocytosis, pinocytosis, or phagocytosis (12) (Figure 1). However, processing of incorporated EVs and their intravesicular content after cellular uptake is entirely unknown. To address this point, tracking experiments using fluorescence labeling represent a possible option to gain further insight into time-dependent cellular processing mechanisms of biological contents transferred by EVs (161). Nevertheless, stable labeling of intravesicular contents is highly demanding technically, and further efforts are needed to improve these techniques (162).

Taken together, there are still serious methodological issues that need to be addressed. Importantly, recent position research papers from the International Society of Extracellular Vesicles have made a first step in the right direction to standardize EV analysis internationally among different laboratories (141,147,153). In addition, EV-TRACK (163), a novel crowd-sourcing database, has recently been implemented, centralizing knowledge about EV biology and methodology with the goal of stimulating authors, reviewers, editors, and funders to put experimental guidelines into practice (164).

**Conclusions**

In the regulation of cardiovascular health and disease, EVs act as urgent effectors by transferring bioactive molecules into adjacent and distant recipients. EV-mediated intercellular vascular signaling results in detrimental and favorable effects on vascular integrity. Studies illustrate that EVs can contribute to atherosclerosis development and progression. In contrast, EVs also emerge as crucial regulators of vascular homeostasis and mediate...
vascular protection. Finally, the use of genetically modified EV might represent a novel therapeutic tool in the field of cardiovascular medicine and regenerative therapy (Central Illustration).

**ADDRESS FOR CORRESPONDENCE:** Dr. Felix Jansen, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany. E-mail: felix.jansen@ukbonn.de. OR Dr. Nikos Werner, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany. E-mail: nwerner@uni-bonn.de. OR Dr. Qian Li, Department of Cardiology, Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun 130000, China.

**REFERENCES**

1. Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247:349-58.
2. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011;31:27-33.
3. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial micro-particles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005;45:1622-30.
4. Jansen F, Nickerig G, Werner N. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res 2017;120:1649-57.
5. Mauve SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010;107:1047-57.
6. Kogure T, Yan IK, Lin W-L, Patel T. Extracellular vesicle-mediated transfer of a novel long non-coding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 2013;4:261-72.
7. Rautou P-E, Vion A-C, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011;109:593-606.
8. Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 2013;33:186-92.
9. Boulanger CM, Loyer X, Rautou P-E, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol 2017;14:259-72.
10. Barile L, Moccetti T, Marbán E, Vassalli G. Roles of exosomes in cardioprotection. Eur Heart J 2017;38:1372.
11. Colombo M, Raposo G, Thiéry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89.
12. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83.
13. Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 2009;458:445-52.
14. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosomes into multi-vesicular endosomes. Science 2008;319:1244-7.
15. Baietti MF, Zhang Z, Mortier E, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol 2012;14:677-85.
16. Nabhani JF, Hu R, Oh RS, Cohen SN, Lu Q. Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMVs) at plasma membrane by recruitment of TSG101 protein. Proc Natl Acad Sci U S A 2012;109:4146-51.
17. Jäf N, McGowan DG, Manavski Y, Boon RA, Dimmeler S. Rab7a and Rab27b control secretion of endothelial microRNA through extracellular vesicles. FEBs Lett 2015;589:3182-8.
18. Bobrie A, Colombo M, Raposo G, Thiéry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011;12:1659-68.
19. Ostrowski M, Carmo NB, Krumenich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010;12 Suppl 1-13:19-30.
20. Muralidharan-Chari V, Clancy J, Plou C, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 2009;19:1875-85.
21. Lo S-C, Hung C-Y, Lin D-T, Peng H-C, Huang T-F. Involvement of platelet glycoprotein Ib in platelet microparticle mediated neutrophil activation. J Biomed Sci 2006;13:787-96.
22. Dasgupta SK, Le A, Chavakis T, Rumbaut RE, Thiagarajan P. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles. Blood 2009;113:1332.
23. Murkin J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470-6.
24. Wang J-G, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial cells in an IL-1f-dependent manner. Blood 2011;118:2366-74.
25. Vázquez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015;4:27066.
26. Rain DM, Spinelli SL, Pollock SJ, et al. Peroxin-36 forms a transmembrane complex with receptor gamma and retinoid X receptor transcription factors. Biochim Biophys Acta 2013;1835:38-50.
27. Jiang F, Yang X, Franklin BS, et al. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res 2013;98:94-106.
28. Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-97.
29. Ratjacak J, Wysocky R, Hayek F, Janowska-Wieczorek A, Ratjacak MZ. Membrane-derived microparticles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95.
30. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010;3:484-8.
31. Bang C, Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 2012;44:2060-4.
32. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
33. Libby P, Ridker PM, Hansson GK, Dluözmupe PH. Transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
Endothelial and Immune Cell EVs in CV Health and Disease

Jansen et al. 805

40. Densmore JC, Signorino PR, Ou J, et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006;26:464–71.

41. Brodsky SV, Zhang F, Naslieli A, Golgowsky MS. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004;286:H1910–9.

42. Boulanger CM, Saoazar E, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001;104:2649–52.

43. Amabile N, Guerin AP, Leroy E, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381–8.

44. Agouln I, Lagrue-Lak-Hal AH, Ducluzeau PH, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008;173:1210–9.

45. Donadee C, Rant NH, Kanius T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011;124:465–76.

46. Gambim MH, do Carmo A de O, Marti L, Verissimo-Filho S, Lopes LR, Janiszewski M. Platelet-derived exosomes induce endothelial cell apoptosis through peroxisome proliferation: experimental evidence for a novel mechanism of septic vascular dysfunction. Crit Care 2007;11:R107.

47. Willessness JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:18–20.

48. Yamamoto S, Nida S, Azuma E, et al. Inflammation-induced endothelial cell-derived extracellular vesicles modulate the cellular status of pericytes. Sci Rep 2015;5:15805.

49. Buzaí E, György B, Nagy G, Falus A, Gay S. Membrane vesicles modulate the cellular status of pericytes. Sci Rep 2015;5:8505.

50. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014;14:56–64.

51. Robbins PD, Gorosoro A, Booker CN. Regulation of chronic inflammatory and immune processes by extracellular vesicles. J Clin Invest 2012;123:1173–80.

52. Mesri M, Altfle DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998;161:4382–7.

53. Mesri M, Altfle DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999;274:23111–8.

54. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001;158:277–87.

55. Barry OP, Pratcib D, Savanti RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998;102:136–44.

56. Huber J, Vales A, Mitulovic G, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2002;22:101–7.

57. Edríss H, Sonck SC, Hakim AM, Thompson CS. Microparticles generated during chronic cerebral ischemia increase the permeability of microvascular endothelial barriers in vitro. Brain Res 2016;1634:83–93.

58. Mause SF, Hundelshausen von P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005;25:1512–8.

59. Vasina EM, Caxwenberghs S, Feigje MAH, Heemskerk JWM, Weber C, Koenen RR. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis 2011;2:e211.

60. de Jong OG, Verhaar MC, Chen Y, et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J ExtracELL Vesicles 2012;1.

61. Alexandru N, Badila E, Weiss E, Cochior D, Stepien I, Georgescu A. Vascular complications in diabetes: microparticles and microparticle-associated microRNAs as active players. Biochem Biophys Res Commun 2016;472:1–10.

62. Wang Y, Chen L-M, Liu M-L. Microvesicles and diabetic complications—novel mediators, potential biomarkers and therapeutic targets. Acta Pharmacol Sin 2014;35:433–43.

63. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. Curr Opin Lipidol 2015;26:412–9.

64. Liu M-L, Williams KJ. Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes 2012;19:121–7.

65. Tang N, Sun B, Gupta A, Rempel H, Pulliam L. Oxidized cell membrane vesicles and blebs from apoptotic cells impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2007;212:174.

66. Weber A, Köppen HO, Schürk K. Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res 2000;98:461–6.

67. Pakala R. Serrotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc Radiat Med 2004;5:520–6.

68. Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One 2009;4:e7140.

69. Krohn JB, Hutcheson JD, Martínez-Martínez E, Aikawa E. Extracellular vesicles in cardiovascular calcification: expanding current paradigms. J Physiol (Lond) 2016;594:2895–903.

70. Goettsch C, Hutcheson JD, Aikawa E, Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Invest 2016;126:1233–36.

71. Hutcheson JD, Goettsch C, Bertazzio S, et al. Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques. Nat Mater 2016;15:335–43.

72. Virmani R, Kolodge SJ, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intra-plaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054–61.

73. Leroy E, Rautou P-E, Silvestre J-S, et al. CD40 ligand microvesicles from human atherosclerotic plaques stimulate monocyte/macrophage differentiation and angiogenesis a potential mechanism for intra-plaque neovascularization. J Am Coll Cardiol 2008;52:1302–11.

74. Hoyer F, Nickenberg G, Werner N. Microparticles—messengers of biological information. J Cell Mol Med 2010;14:2250–6.

75. Mallat Z, Hugel B, Ohan J, Lescège G, Freysinet JM, Tedgui A. Shed membrane micro-particles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348–53.
Biró E, Sturk-Maquelin KN, Vogel GMT, et al. Hematopoietic cell-derived microparticle tissue factor-bearing microparticles and thrombus formation in vivo in a tissue factor-mimetic model. Thromb Haemost 2003;1:2561–7.

105. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol 1997;62 Suppl 2:523–9.

106. Leroyer AS, Ebrahimian TG, Cochain C, et al. MicroRNAs from ischemic muscle promote postnatal vasculogenesis. Circulation 2009;119:2008–17.

107. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010;4:214–22.

108. Vrijen KR, Sluijter JPG, Schuchardt MWL, et al. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. J Cell Mol Med 2010;14:1064–70.

109. Mackie AR, Klyachko E, Thorne T, et al. Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction. Circ Res 2012;111:312–21.

110. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res 2015;117:52–64.

111. Noma S, Iwakura Y, Masuda M, et al. Exosomes derived from mesenchymal stem cells: potent angiogenic agents. Biol Chem 2010;391:133–44.

112. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting siRNAs deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650–6.

113. Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)–dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 2012;109:E1695–704.

114. Muthiah M, Park I-K, Cho C-S. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Exp Opin Drug Deliv 2013;10:1259–73.

115. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm 2012;9:1481–91.

116. Anand S, Majeti BK, Acedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010;16:909–14.

117. Mokarizadeh A, Delirneh N, Moshedi A, Mosayebi G, Farshid A-A, Mardani K. Microvesicles derived from mesenchymal stem cells: potent agents for induction of tolerogenic signaling. Immunol Lett 2012;147:44–57.

118. Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 2013;10:301–12.

119. Zou X, Zhang G, Cheng Z, et al. Microvesicles derived from human Wharton’s jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Res Ther 2014;5:40.

120. Hergenreider E, Heydt S, Trüger K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012;14:249–56.

121. Shan Z, Qin S, Li W, et al. An Endocrine genetic signal between blood cells and vascular smooth muscle cells: role of miRNA-223 in smooth muscle function and atherogenesis. J Am Coll Cardiol 2015;65:2526–37.

122. Srikantan S, Li W, Silverstein RL, McIntyre TM. Exosome poly-ubiquitin inhibits platelet activation, downregulates CD47 and inhibits pro-atherothrombotic cellular functions. J Thromb Haemost 2014;12:1906–17.

123. Zhang Y, Liu D, Chen X, et al. Secreted microRNA-150 enhances targeted endothelial cell migration. Mol Cell 2010;39:133–44.

124. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting siRNAs deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650–6.
Endothelial and Immune Cell EVs in CV Health and Disease

KEY WORDS cardiovascular disease, extracellular vesicles, microvesicles